Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.

Dvorak CC, Horn BN, Puck JM, Adams S, Veys P, Czechowicz A, Cowan MJ.

Pediatr Transplant. 2014 Sep;18(6):609-16. doi: 10.1111/petr.12310. Epub 2014 Jun 30.

2.

A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.

Dvorak CC, Horn BN, Puck JM, Czechowicz A, Shizuru JA, Ko RM, Cowan MJ.

Pediatr Transplant. 2014 Sep;18(6):602-8. doi: 10.1111/petr.12309. Epub 2014 Jun 30.

3.

Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency.

Hassan A, Lee P, Maggina P, Xu JH, Moreira D, Slatter M, Nademi Z, Worth A, Adams S, Jones A, Cale C, Allwood Z, Rao K, Chiesa R, Amrolia P, Gaspar H, Davies EG, Veys P, Gennery A, Qasim W.

J Allergy Clin Immunol. 2014 Jun;133(6):1660-6. doi: 10.1016/j.jaci.2014.02.042. Epub 2014 May 1. Erratum in: J Allergy Clin Immunol. 2016 Apr;137(4):1286.

4.

Multilineage hematopoietic engraftment after allogeneic peripheral blood stem cell transplantation without conditioning in SCID patients.

Bielorai B, Trakhtenbrot L, Amariglio N, Rothman R, Tabori U, Dallal I, Golan H, Neumann Y, Reichart M, Kaplinsky C, Rechavi G, Toren A.

Bone Marrow Transplant. 2004 Aug;34(4):317-20.

PMID:
15220954
5.
6.

In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.

Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, Kondo Y, Nakao S, Nagafuji K, Miyamoto T, Kurokawa M, Okoshi Y, Chiba S, Ohashi Y, Takaue Y, Taniguchi S.

Am J Hematol. 2013 Apr;88(4):294-300. doi: 10.1002/ajh.23392. Epub 2013 Feb 28.

7.

Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency.

Dvorak CC, Hassan A, Slatter MA, Hönig M, Lankester AC, Buckley RH, Pulsipher MA, Davis JH, Güngör T, Gabriel M, Bleesing JH, Bunin N, Sedlacek P, Connelly JA, Crawford DF, Notarangelo LD, Pai SY, Hassid J, Veys P, Gennery AR, Cowan MJ.

J Allergy Clin Immunol. 2014 Oct;134(4):935-943.e15. doi: 10.1016/j.jaci.2014.06.021. Epub 2014 Aug 7.

8.

Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, Myers LA, Ward FE.

N Engl J Med. 1999 Feb 18;340(7):508-16.

9.
10.

Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.

Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA, Horn B.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1656-63. doi: 10.1016/j.bbmt.2012.05.006. Epub 2012 May 15.

11.

Kinetics of T-cell development of umbilical cord blood transplantation in severe T-cell immunodeficiency disorders.

Knutsen AP, Wall DA.

J Allergy Clin Immunol. 1999 May;103(5 Pt 1):823-32.

PMID:
10329816
12.
13.

Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency.

Hassan A, Booth C, Brightwell A, Allwood Z, Veys P, Rao K, Hönig M, Friedrich W, Gennery A, Slatter M, Bredius R, Finocchi A, Cancrini C, Aiuti A, Porta F, Lanfranchi A, Ridella M, Steward C, Filipovich A, Marsh R, Bordon V, Al-Muhsen S, Al-Mousa H, Alsum Z, Al-Dhekri H, Al Ghonaium A, Speckmann C, Fischer A, Mahlaoui N, Nichols KE, Grunebaum E, Al Zahrani D, Roifman CM, Boelens J, Davies EG, Cavazzana-Calvo M, Notarangelo L, Gaspar HB; Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation and European Society for Immunodeficiency..

Blood. 2012 Oct 25;120(17):3615-24; quiz 3626. doi: 10.1182/blood-2011-12-396879. Epub 2012 Jul 12.

14.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70. doi: 10.1016/j.bbmt.2015.04.009. Epub 2015 Apr 10.

15.

Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.

Ahmed N, Leung KS, Rosenblatt H, Bollard CM, Gottschalk S, Myers GD, Carrum G, Heslop HE, Brenner MK, Krance RA.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1298-304. doi: 10.1016/j.bbmt.2008.09.003.

16.

Relationship between patterns of engraftment in peripheral blood and immune reconstitution after allogeneic bone marrow transplantation for (severe) combined immunodeficiency.

van Leeuwen JE, van Tol MJ, Joosten AM, Schellekens PT, van den Bergh RL, Waaijer JL, Oudeman-Gruber NJ, van der Weijden-Ragas CP, Roos MT, Gerritsen EJ, et al.

Blood. 1994 Dec 1;84(11):3936-47. Review.

17.
18.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. Epub 2007 Sep 14.

PMID:
17869547
19.

HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia.

Zecca M, Strocchio L, Pagliara D, Comoli P, Bertaina A, Giorgiani G, Perotti C, Corbella F, Brescia L, Locatelli F.

Biol Blood Marrow Transplant. 2014 Apr;20(4):571-6. doi: 10.1016/j.bbmt.2014.01.015. Epub 2014 Jan 22.

20.

Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.

Straathof KC, Rao K, Eyrich M, Hale G, Bird P, Berrie E, Brown L, Adams S, Schlegel PG, Goulden N, Gaspar HB, Gennery AR, Landais P, Davies EG, Brenner MK, Veys PA, Amrolia PJ.

Lancet. 2009 Sep 12;374(9693):912-20. doi: 10.1016/S0140-6736(09)60945-4. Epub 2009 Sep 2.

PMID:
19729196

Supplemental Content

Support Center